Colorectal cancer (CRC) and uterine serous carcinoma are among the major cancer types where NGS is advocated as the initial testing approach for detecting ERBB2 amplification to identify eligible patients for targeted therapies [3,12,13]; however, the limitations, sensitivity, and specificity of various NGS panels in detecting such amplifications have not been adequately addressed in these studies [12,13]. Here, ERBB2 is linked to cancer.